<p>佛罗里达州朱庇特，2025 年 12 月 15 日（全球新闻通讯社）—— <strong>Dyadic Applied BioSolutions（“Dyadic”）（纳斯达克：DYAI）</strong> 是一家全球生物技术公司，专注于在生命科学、食品与营养以及生物工业市场中生产精确工程化的无动物蛋白和酶。今天宣布与 Opes Diagnostics Limited（“Opes”）达成商业协议，以支持 Dyadic 重组人转铁蛋白、牛转铁蛋白、人 FGF 和牛 FGF 产品在无血清细胞培养基应用中的商业推出。</p>
<p>根据协议，Opes 将利用其现有的商业关系和市场经验，主要在欧洲、以色列和亚洲识别和接触潜在客户，以加速 Dyadic 重组蛋白产品在细胞培养基及相关应用中的市场进入，同时 Dyadic 保留直接销售和与全球其他合作伙伴合作的能力。</p>
<p>此次合作旨在加速 Dyadic 利用其微生物表达平台生产的重组蛋白产品在研究、诊断、培养肉和生命科学生物制造等行业的渗透，这些行业需要可靠、可扩展且具有成本效益的生长因子和功能性蛋白来源。Opes 已经为多家使用无血清细胞培养基的客户提供了样品，应用于生命科学、食品和营养领域。</p>
<p>“这次合作通过与在我们服务的行业中拥有强大现有关系的合作伙伴扩展我们的重组蛋白产品组合，支持我们的商业目标，” Dyadic Applied BioSolutions 总裁兼首席运营官 Joe Hazelton 表示。“Opes 的市场存在和客户网络预计将有助于推动 Dyadic 细胞培养基产品在不断扩展的市场中的采用，并进一步推动我们从主要的开发活动转向更广泛的商业参与。”</p>
<p><strong>关于 Dyadic Applied BioSolutions</strong></p>
<p>Dyadic Applied BioSolutions 是一家全球生物技术公司，利用其专有的微生物平台生产重组蛋白，这些蛋白被销售或授权给生命科学、食品与营养以及生物工业市场的合作伙伴。这些高质量的蛋白旨在帮助客户开发更高效、可扩展和可持续的产品。Dyadic 的 C1 和 Dapibus™表达系统支持灵活、具有成本效益的制造，并且是不断增长的商业和合作项目组合的基础。有关 Dyadic 的更多信息，请访问 www.dyadic.com</p>
<p><strong>关于 Opes Diagnostics Limited</strong></p>
<p>Opes Diagnostics Limited 是一家总部位于英国的诊断工具、实验室耗材和生物试剂的提供商，在欧洲和其他国际市场上拥有成熟的客户关系。Opes 为生物技术、诊断及相关领域的一系列产品提供商业化支持。</p>
<p><strong>前瞻性声明的安全港</strong></p>
<p>本新闻稿包含根据《证券法》第 27A 节和《交易法》第 21E 节的定义的前瞻性声明，包括 Dyadic 对未来事件或未来财务表现的预期、意图、策略和信念，例如 Dyadic 临床试验的成功及其蛋白生产平台的兴趣、Dyadic 的研究项目和第三方合作，以及必要资金的可用性。前瞻性声明涉及许多超出 Dyadic 控制的风险、不确定性或其他因素。这些因素包括但不限于以下内容：（i）Dyadic 的净亏损历史；（ii）市场和监管对 Dyadic 微生物蛋白生产平台及其他技术的接受；（iii）未能商业化 Dyadic 的微生物蛋白生产平台或其他技术；（iv）竞争，包括来自替代技术的竞争；（v）非临床研究和临床试验的结果；（vi）Dyadic 的资本需求；（vii）全球经济和金融状况的变化；（viii）Dyadic 对信息技术的依赖；（ix）Dyadic 对第三方的依赖；（x）政府法规及环境、社会和治理问题；（xi）知识产权风险；（xii）Dyadic 遵守纳斯达克证券市场上市标准的能力。有关可能导致 Dyadic 实际结果与其当前预期不同的风险的更完整描述，请参见 Dyadic 提交给 SEC 的 10-K 年报和 10-Q 季度报告中的 “风险因素” 部分，这些因素可能会不时在 Dyadic 定期向 SEC 提交的文件中更新，这些文件可在 SEC 网站和 www.dyadic.com 上获取。所有前瞻性声明仅在发布之日有效，除非法律要求，Dyadic 不承担在本新闻稿发布后出于任何原因公开更新任何此类前瞻性声明以使其与实际结果或 Dyadic 的预期变化相符的义务。</p>
<p>媒体联系人：</p>
<p>Dyadic Applied BioSolutions：</p>
<p>Ping Rawson</p>
<p>首席财务官</p>
<p>电话：（561）743-8333</p>
<p>电子邮件：ir@dyadic.com</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RZd01UazJOU00zTXpJeE1qZzVJekl3TVRreU1UQT0?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="1" height="1" original-src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RZd01UazJOU00zTXpJeE1qZzVJekl3TVRreU1UQT0"/></p>
<p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/ZWU3NDkxNjQtZmEyMS00YjAxLWIyYTYtMDI2Y2JlMWUyZGM2LTEwMzA3ODMtMjAyNS0xMi0xNS1lbg==/tiny/Dyadic-International-Inc-.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="1" height="1" original-src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/ZWU3NDkxNjQtZmEyMS00YjAxLWIyYTYtMDI2Y2JlMWUyZGM2LTEwMzA3ODMtMjAyNS0xMi0xNS1lbg==/tiny/Dyadic-International-Inc-.png"/></p>

DYAI

<p>Dyadic Applied BioSolutions 与 Opes Diagnostics Limited 达成了一项商业协议，以支持 Dyadic 在生命科学、食品和营养市场推出重组蛋白用于无血清细胞培养基。Opes 将利用其市场经验在欧洲、以色列和亚洲识别潜在客户。此次合作旨在加速 Dyadic 蛋白产品在研究、诊断和生物制造等各个行业的应用</p>

<p>JUPITER, Fla., Dec. 15, 2025 (GLOBE NEWSWIRE) -- <strong>Dyadic Applied BioSolutions (“Dyadic”) (NASDAQ: DYAI)</strong>, a global biotechnology company producing precision-engineered, animal-free proteins and enzymes across life science, food &amp; nutrition, and bioindustrial markets today announced that it has entered into a commercial agreement with Opes Diagnostics Limited (“Opes”) to support the commercial launch of Dyadic’s recombinant human transferrin, bovine transferrin, human FGF, and bovine FGF products for use in serum-free cell culture media applications in the life science, food and nutrition markets.</p>
<div class="lb-trans"><p>佛罗里达州朱庇特，2025 年 12 月 15 日（全球新闻通讯社）—— <strong>Dyadic Applied BioSolutions（“Dyadic”）（纳斯达克：DYAI）</strong> 是一家全球生物技术公司，专注于在生命科学、食品与营养以及生物工业市场中生产精确工程化的无动物蛋白和酶。今天宣布与 Opes Diagnostics Limited（“Opes”）达成商业协议，以支持 Dyadic 重组人转铁蛋白、牛转铁蛋白、人 FGF 和牛 FGF 产品在无血清细胞培养基应用中的商业推出。</p>
</div><p>Under the agreement, Opes will leverage its existing commercial relationships and market experience to identify and engage potential customers primarily in Europe, Israel, and Asia to accelerate market entry for Dyadic’s recombinant protein portfolio in cell culture media and related applications, while Dyadic retains the ability to sell directly and to work with additional partners globally.</p>
<div class="lb-trans"><p>根据协议，Opes 将利用其现有的商业关系和市场经验，主要在欧洲、以色列和亚洲识别和接触潜在客户，以加速 Dyadic 重组蛋白产品在细胞培养基及相关应用中的市场进入，同时 Dyadic 保留直接销售和与全球其他合作伙伴合作的能力。</p>
</div><p>The collaboration is intended to accelerate the penetration of Dyadic’s recombinant protein products produced using its microbial expression platforms in industries including research, diagnostics, cultured meat and life sciences biomanufacturing that require reliable, scalable, and cost-effective sources of growth factors and functional proteins. Opes has already sampled multiple customers utilizing serum free cell culture media in life sciences, food and nutrition applications.</p>
<div class="lb-trans"><p>此次合作旨在加速 Dyadic 利用其微生物表达平台生产的重组蛋白产品在研究、诊断、培养肉和生命科学生物制造等行业的渗透，这些行业需要可靠、可扩展且具有成本效益的生长因子和功能性蛋白来源。Opes 已经为多家使用无血清细胞培养基的客户提供了样品，应用于生命科学、食品和营养领域。</p>
</div><p>“This collaboration supports our commercial objectives by extending our recombinant protein portfolio in target markets with a partner that has strong, existing sector relationships within the sectors we serve,” said Joe Hazelton, President &amp; COO of Dyadic Applied BioSolutions. “Opes’ market presence and customer network are expected to help drive adoption of Dyadic’s cell culture media products into expanding markets and to further our shift from primarily development activities to broader commercial engagement.”</p>
<div class="lb-trans"><p>“这次合作通过与在我们服务的行业中拥有强大现有关系的合作伙伴扩展我们的重组蛋白产品组合，支持我们的商业目标，” Dyadic Applied BioSolutions 总裁兼首席运营官 Joe Hazelton 表示。“Opes 的市场存在和客户网络预计将有助于推动 Dyadic 细胞培养基产品在不断扩展的市场中的采用，并进一步推动我们从主要的开发活动转向更广泛的商业参与。”</p>
</div><p><strong>About Dyadic Applied BioSolutions</strong></p>
<div class="lb-trans"><p><strong>关于 Dyadic Applied BioSolutions</strong></p>
</div><p>Dyadic Applied BioSolutions is a global biotechnology company that uses its proprietary microbial platforms to produce recombinant proteins that are sold or licensed to partners across the life sciences, food and nutrition, and bio-industrial markets. These high-quality proteins are designed to enable customers to develop more efficient, scalable, and sustainable products. Dyadic’s C1 and Dapibus™ expression systems support flexible, cost-effective manufacturing, and are the foundation of a growing portfolio of commercial and partnered programs. For more information about Dyadic, please visit www.dyadic.com</p>
<div class="lb-trans"><p>Dyadic Applied BioSolutions 是一家全球生物技术公司，利用其专有的微生物平台生产重组蛋白，这些蛋白被销售或授权给生命科学、食品与营养以及生物工业市场的合作伙伴。这些高质量的蛋白旨在帮助客户开发更高效、可扩展和可持续的产品。Dyadic 的 C1 和 Dapibus™表达系统支持灵活、具有成本效益的制造，并且是不断增长的商业和合作项目组合的基础。有关 Dyadic 的更多信息，请访问 www.dyadic.com</p>
</div><p><strong>About Opes Diagnostics Limited</strong></p>
<div class="lb-trans"><p><strong>关于 Opes Diagnostics Limited</strong></p>
</div><p>Opes Diagnostics Limited is a United Kingdom–based provider of diagnostic tools, laboratory consumables, and biological reagents, with established customer relationships across Europe and other international markets. Opes offers commercialization support for a range of products used in biotechnology, diagnostics, and related fields.</p>
<div class="lb-trans"><p>Opes Diagnostics Limited 是一家总部位于英国的诊断工具、实验室耗材和生物试剂的提供商，在欧洲和其他国际市场上拥有成熟的客户关系。Opes 为生物技术、诊断及相关领域的一系列产品提供商业化支持。</p>
</div><p><strong>Safe Harbor Regarding Forward-Looking Statements</strong></p>
<div class="lb-trans"><p><strong>前瞻性声明的安全港</strong></p>
</div><p>This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Exchange Act, including those regarding Dyadic’s expectations, intentions, strategies, and beliefs pertaining to future events or future financial performance, such as the success of Dyadic’s clinical trial and interest in its protein production platforms, Dyadic’s research projects and third-party collaborations, as well as the availability of necessary funding. Forward-looking statements involve many risks, uncertainties or other factors beyond Dyadic’s control. These factors include, but are not limited to, the following: (i) Dyadic’s history of net losses; (ii) market and regulatory acceptance of Dyadic’s microbial protein production platforms and other technologies; (iii) failure to commercialize Dyadic’s microbial protein production platforms or its other technologies; (iv) competition, including from alternative technologies; (v) the results of nonclinical studies and clinical trials; (vi) Dyadic’s capital needs; (vii) changes in global economic and financial conditions; (viii) Dyadic’s reliance on information technology; (ix) Dyadic’s dependence on third parties; (x) government regulations and environmental, social and governance issues; (xi) intellectual property risks; and (xii) Dyadic’s ability to comply with the listing standards of the Nasdaq Stock Market LLC. For a more complete description of the risks that could cause Dyadic’s actual results to differ from its current expectations, please see the section entitled “Risk Factors” in Dyadic’s annual reports on Form 10-K and quarterly reports on Form 10-Q filed with the SEC, as such factors may be updated from time to time in Dyadic’s periodic filings with the SEC, which are accessible on the SEC’s website and at www.dyadic.com. All forward-looking statements speak only as of the date made, and except as required by applicable law, Dyadic assumes no obligation to publicly update any such forward-looking statements for any reason after the date of this press release to conform these statements to actual results or to changes in Dyadic’s expectations.</p>
<div class="lb-trans"><p>本新闻稿包含根据《证券法》第 27A 节和《交易法》第 21E 节的定义的前瞻性声明，包括 Dyadic 对未来事件或未来财务表现的预期、意图、策略和信念，例如 Dyadic 临床试验的成功及其蛋白生产平台的兴趣、Dyadic 的研究项目和第三方合作，以及必要资金的可用性。前瞻性声明涉及许多超出 Dyadic 控制的风险、不确定性或其他因素。这些因素包括但不限于以下内容：（i）Dyadic 的净亏损历史；（ii）市场和监管对 Dyadic 微生物蛋白生产平台及其他技术的接受；（iii）未能商业化 Dyadic 的微生物蛋白生产平台或其他技术；（iv）竞争，包括来自替代技术的竞争；（v）非临床研究和临床试验的结果；（vi）Dyadic 的资本需求；（vii）全球经济和金融状况的变化；（viii）Dyadic 对信息技术的依赖；（ix）Dyadic 对第三方的依赖；（x）政府法规及环境、社会和治理问题；（xi）知识产权风险；（xii）Dyadic 遵守纳斯达克证券市场上市标准的能力。有关可能导致 Dyadic 实际结果与其当前预期不同的风险的更完整描述，请参见 Dyadic 提交给 SEC 的 10-K 年报和 10-Q 季度报告中的 “风险因素” 部分，这些因素可能会不时在 Dyadic 定期向 SEC 提交的文件中更新，这些文件可在 SEC 网站和 www.dyadic.com 上获取。所有前瞻性声明仅在发布之日有效，除非法律要求，Dyadic 不承担在本新闻稿发布后出于任何原因公开更新任何此类前瞻性声明以使其与实际结果或 Dyadic 的预期变化相符的义务。</p>
</div><p>Media contacts:</p>
<div class="lb-trans"><p>媒体联系人：</p>
</div><p>Dyadic Applied BioSolutions:</p>
<div class="lb-trans"><p>Dyadic Applied BioSolutions：</p>
</div><p>Ping Rawson</p>
<div class="lb-trans"><p>Ping Rawson</p>
</div><p>Chief Financial Officer</p>
<div class="lb-trans"><p>首席财务官</p>
</div><p>Phone: (561) 743-8333</p>
<div class="lb-trans"><p>电话：（561）743-8333</p>
</div><p>Email: ir@dyadic.com</p>
<div class="lb-trans"><p>电子邮件：ir@dyadic.com</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RZd01UazJOU00zTXpJeE1qZzVJekl3TVRreU1UQT0" alt="" original-src="https://www.globenewswire.com/newsroom/ti?nf=OTYwMTk2NSM3MzIxMjg5IzIwMTkyMTA="/></p>
<p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/ZWU3NDkxNjQtZmEyMS00YjAxLWIyYTYtMDI2Y2JlMWUyZGM2LTEwMzA3ODMtMjAyNS0xMi0xNS1lbg==/tiny/Dyadic-International-Inc-.png" alt="" original-src="https://ml.globenewswire.com/media/ZWU3NDkxNjQtZmEyMS00YjAxLWIyYTYtMDI2Y2JlMWUyZGM2LTEwMzA3ODMtMjAyNS0xMi0xNS1lbg==/tiny/Dyadic-International-Inc-.png"/></p>

Dyadic Applied BioSolutions Establishes Commercial Partnership to Accelerate Adoption of Dyadic’s Recombinant Growth Factors and Media Proteins | DYAI Stock News

Dyadic 应用生物解决方案公司建立商业合作伙伴关系，以加速 Dyadic 重组生长因子和培养基蛋白的采用 | DYAI 股票新闻